Healthcare Providers and Services
Company Overview of National Cancer Center
National Cancer Center operates as a hospital that focuses on cancer treatment and clinical research services. The company provides patient care services, which include maintenance of clinics and wards, diagnosis and treatment by means of diagnostic tools, proton therapy, palliative care, and volunteering activities. Its research institute offers development of treatment methods and diagnostic procedures. The company's oncology research and clinical trial center unites doctors and researchers for development of drugs and medical equipment. In addition, it gathers and disseminates cancer related information to community and recommends initiatives and policies to government. National Cancer Ce...
Founded in 1962
Key Executives for National Cancer Center
Chief-Office-Advncd Medical Careevaluation & Health Tech assessment & Director-Strategic Planning
Chief of Research Audit Section and Director of Center for Researchadministration and Support
Director of Administrative Departments
Director of Center for Education Andprofessional Career Development
Compensation as of Fiscal Year 2016.
National Cancer Center Key Developments
Daiichi Sankyo (Japan) Enters into Collaboration with National Cancer Center of Japan
Mar 2 17
Daiichi Sankyo (Japan) has entered into a collaboration with the National Cancer Center of Japan to develop an inhibitor for DS-1001 (mutant isocitrate dehydrogenase IDH1) as a new treatment for gliomas (malignant brain tumours), the parties said in a statement. In addition, the two parties aim to initiate a multi-centre Phase I clinical trial of DS-1001 in patients with recurrent IDH1 mutant gliomas who have no standard treatment. IDH1 and IDH2 gene mutations are frequently observed in patients with malignant tumours such as gliomas, acute myeloid leukaemia (AML), cholangiocarcinoma, and chondrosarcoma. IDH1 gene mutations are observed in more than 70% of patients diagnosed as grade 2 or 3 gliomas (astrocytomas or oligodendrogliomas), with cases most frequently observed in people aged 30-50 years. The collaboration agreement follows research by the National Cancer Center Research Institute's showing that inhibition of mutant IDH1/2 was able to eliminate AML cancer stem cells, and preclinical studies also demonstrated that DS-1001 was effective in suppressing the proliferation of AML, malignant gliomas, and chondrosarcoma. The collaboration reflects a growing trend of corporate-academia partnerships in Japan, which have the advantage of aligning academic research more closely with market and patient demand, as well as corporate funding. In particular, the agreement further extends Japan's National Cancer Center's series of collaborations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries